Indication from Summary of Product Characteristics

PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
slide overlay image
PIK3CA mutations
are a common
indicator of
poor prognosis1-8
Learn more about the PIK3CA mutation
Progression free chart image Progression free chart image
slide overlay image
PIQRAY specifically
addresses PIK3CA
Find out how
PIQRAY works
play button
first video image first video image
slide overlay image
Nearly doubled mPFS
in patients with a
PIK3CA mutation9,10
See the efficacy
Progression free chart image Progression free chart image
Downloadable management
Stay up to date with key information
for treatment management
Start your checklist
slide overlay image
Keeping TRAQ with PIQRAY:
Patient Management Tool
Click through relevant
considerations for selected ARs
Explore the Tool
Progression free chart image Progression free chart image
References: 1. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. 2. Tolaney S, Toi M, Neven P, et al. Presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA. 3. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100. 4. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730. 5. Mosele F,
Stefanovska B,
Lusque A,
et al.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386. 6. Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292. 7. Li YL, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96(1):91-95. 8. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzsen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15(4):1064-1069. 9. Piqray® (alpelisib) EU Summary of Product Characteristics. Novartis; August 2020. 10. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.